Stockscreener 앱 받기
1.08
0.00%
0.00
시간 외 거래:
1.06
-0.02
-1.85%
전일 마감가:
$1.08
열려 있는:
$1.06
하루 거래량:
54,762
Relative Volume:
0.07
시가총액:
$36.93M
수익:
$3.04M
순이익/손실:
$-33.97M
주가수익비율:
-0.812
EPS:
-1.33
순현금흐름:
$-52.47M
1주 성능:
-1.82%
1개월 성능:
-10.74%
6개월 성능:
-55.56%
1년 성능:
-84.90%
1일 변동 폭
$1.06
$1.0994
1주일 범위
$1.05
$1.13
52주 변동 폭
$1.02
$7.88
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
명칭
Rani Therapeutics Holdings Inc
전화
(408) 457-3700
주소
2051 RINGWOOD AVENUE, SAN JOSE
RANI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
1.08 | 36.93M | 3.04M | -33.97M | -52.47M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-02 | 개시 | Oppenheimer | Outperform |
| 2024-06-14 | 개시 | Maxim Group | Buy |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-04-17 | 재개 | BTIG Research | Buy |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-07-27 | 개시 | H.C. Wainwright | Buy |
| 2022-06-13 | 개시 | Wedbush | Outperform |
모두보기
Rani Therapeutics Holdings Inc 주식(RANI)의 최신 뉴스
Rani Therapeutics (RANI) Expected to Announce Quarterly Earnings on Monday - Defense World
Rani Therapeutics Board Restructures After DeBuono’s Retirement - TipRanks
Ratio Examination: Rani Therapeutics Holdings Inc (RANI)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Daily Progress: XPLR Infrastructure LP (XIFR) Drop -1.51, Closing at 8.46 - DWinneX
Market Recap: PowerFleet Inc (AIOT)’s Negative Momentum, Closing at 5.12 - DWinneX
Market Highlights: Clear Channel Outdoor Holdings Inc (CCO) Ends on a Low Note at 1.02 - DWinneX
Post-Trade Analysis: Baytex Energy Corp (BTE) Climbs 0.61, Closing at 1.65 - DWinneX
Brokerages Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Target Price at $12.33 - Defense World
SEC Form DEFA14A filed by Rani Therapeutics Holdings Inc. - Quantisnow
HC Wainwright Reaffirms “Buy” Rating for Rani Therapeutics (NASDAQ:RANI) - Defense World
What is Zacks Small Cap’s Forecast for RANI FY2025 Earnings? - Defense World
Rani Therapeutics stock hits 52-week low at $1.24 - Investing.com Australia
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $12.33 Consensus PT from Analysts - Defense World
Rani Therapeutics Earnings Call: Tech Gains Amid Financial Strains - TipRanks
BTIG maintains Buy on Rani Therapeutics stock, $14 target - Investing.com Australia
RANI: 2024 Financial Results - Yahoo Finance
Stifel maintains Buy on Rani Therapeutics, $8 target By Investing.com - Investing.com South Africa
Stifel maintains Buy on Rani Therapeutics, $8 target - Investing.com
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2024 Earnings Call Transcript - Insider Monkey
BTIG maintains Buy on Rani Therapeutics stock, $14 target By Investing.com - Investing.com UK
Virtu Financial LLC Invests $62,000 in Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) - Defense World
Rani Therapeutics Reports 2024 Financial Results and Updates - TipRanks
Earnings call transcript: Rani Therapeutics sees stock drop despite narrowing losses in Q4 2024 - Investing.com Canada
Earnings call transcript: Rani Therapeutics sees stock drop despite narrowing losses in Q4 2024 By Investing.com - Investing.com South Africa
Rani Therapeutics Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update - GlobeNewswire
Breakthrough: Rani's Oral GLP-1 Shows 111% Bioequivalence in Latest Financial Report - Stock Titan
Rani Therapeutics Holdings Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView
An Overview of Rani Therapeutics Hldgs's Earnings - Benzinga
Stifel maintains Buy on Rani Therapeutics stock, $8 target By Investing.com - Investing.com South Africa
Stifel maintains Buy on Rani Therapeutics stock, $8 target - Investing.com India
Rani Therapeutics stock holds buy rating, $14 target from BTIG By Investing.com - Investing.com Canada
Rani Therapeutics reports oral drug matches injectable in obesity study By Investing.com - Investing.com South Africa
Rani Therapeutics reports oral drug matches injectable in obesity study - Investing.com
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence Of RT-114, A GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally Via The RaniPill Capsule, To Subcutaneously Administered PG-102 - MarketScreener
Rani Therapeutics Announces Preclinical Data Demonstrating - GlobeNewswire
Rani Therapeutics (RANI) Announces Preclinical Data Demonstrating Bioequivalence of RT-114 - StreetInsider.com
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102 - Nasdaq
Rani Therapeutics stock holds buy rating, $14 target from BTIG - Investing.com India
Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Oral Biologics Pioneer Rani Therapeutics Announces 2024 Year-End Earnings Date - Stock Titan
Rani Therapeutics (RANI) Expected to Announce Earnings on Wednesday - Armenian Reporter
Head to Head Survey: Rani Therapeutics (NASDAQ:RANI) vs. CalciMedica (NASDAQ:CALC) - The AM Reporter
Rani Therapeutics (RANI) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Rani Therapeutics (NASDAQ:RANI) versus CalciMedica (NASDAQ:CALC) Financial Contrast - Defense World
Brokerages Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Price Target at $12.33 - Defense World
Canaccord Genuity Group Reaffirms “Buy” Rating for Rani Therapeutics (NASDAQ:RANI) - The AM Reporter
Rani Therapeutics’ (RANI) Buy Rating Reiterated at Canaccord Genuity Group - Defense World
Canaccord Genuity Group Reiterates Buy Rating for Rani Therapeutics (NASDAQ:RANI) - MarketBeat
RANI: Impressive Bioavailability for RT-116 - Yahoo Finance
Power to the People: How Individual Investors Shape Rani Therapeutics - Smartphone Magazine
Rani Therapeutics Holdings Inc (RANI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):